Unique Bioactives from Zombie Fungus ( Cordyceps ) as Promising Multitargeted Neuroprotective Agents.
Himadri SharmaNiti SharmaSeong Soo Alexander AnPublished in: Nutrients (2023)
Cordyceps , also known as "zombie fungus", is a non-poisonous mushroom that parasitizes insects for growth and development by manipulating the host system in a way that makes the victim behave like a "zombie". These species produce promising bioactive metabolites, like adenosine, β-glucans, cordycepin, and ergosterol. Cordyceps has been used in traditional medicine due to its immense health benefits, as it boosts stamina, appetite, immunity, longevity, libido, memory, and sleep. Neuronal loss is the typical feature of neurodegenerative diseases (NDs) (Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS)) and neurotrauma. Both these conditions share common pathophysiological features, like oxidative stress, neuroinflammation, and glutamatergic excitotoxicity. Cordyceps bioactives (adenosine, N 6 -(2-hydroxyethyl)-adenosine, ergosta-7, 9 (11), 22-trien-3β-ol, active peptides, and polysaccharides) exert potential antioxidant, anti-inflammatory, and anti-apoptotic activities and display beneficial effects in the management and/or treatment of neurodegenerative disorders in vitro and in vivo. Although a considerable list of compounds is available from Cordyceps , only a few have been evaluated for their neuroprotective potential and still lack information for clinical trials. In this review, the neuroprotective mechanisms and safety profile of Cordyceps extracts/bioactives have been discussed, which might be helpful in the identification of novel potential therapeutic entities in the future.
Keyphrases
- amyotrophic lateral sclerosis
- cerebral ischemia
- multiple sclerosis
- anti inflammatory
- oxidative stress
- clinical trial
- ms ms
- protein kinase
- cell death
- subarachnoid hemorrhage
- mental health
- machine learning
- traumatic brain injury
- mass spectrometry
- health information
- brain injury
- public health
- randomized controlled trial
- human health
- deep learning
- physical activity
- climate change
- current status
- lipopolysaccharide induced
- sleep quality
- risk assessment
- cognitive decline
- ischemia reperfusion injury
- cognitive impairment
- open label
- depressive symptoms
- double blind
- combination therapy
- induced apoptosis
- tissue engineering
- neural network
- phase ii
- phase iii